罕见的质瘤:标准治疗方法和新的向疗法
Francesco Bruno1, Alessia Pellerino, Edoardo Pronello
1Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.
Current opinion in neurology
|September 24, 2025
概括
罕见的质瘤需要除了手术和放射外的新疗法. 分子向疗法,如BRAF和NTRK抑制剂,对这些具有挑战性的中枢神经系统 (CNS) 瘤显示出希望.
科学领域:
- 神经瘤学神经瘤学
- 分子病理学分子病理学
- 精准医学是一门精准的医学.
背景情况:
- 罕见的质瘤是中枢神经系统 (CNS) 瘤的异质群体,治疗选择有限.
- 传统的治疗包括手术和放射治疗,但疗效往往有限.
- 分子分析的进步已经确定了可操作的目标,需要重新评估治疗策略.
研究的目的:
- 审查目前用于罕见质瘤的标准治疗方法.
- 描述罕见质瘤分子向治疗的最新进展.
- 突出精确瘤学推动的不断变化的治疗环境.
主要方法:
- 对当前标准治疗方法的文献综述.
- 对最近关于分子向疗法的研究进行分析.
- 对罕见的中枢神经系统瘤的精密瘤学方法的综合发现.
主要成果:
- 整体手术切除是最佳瘤控制的主要治疗方法.
- 放射治疗对亚总切除或复发性疾病提供了额外的益处.
- 包括BRAF/MAPK,NTRK,FGFR和mTOR抑制剂在内的向疗法在选择的罕见质瘤群体中表现出显著的临床活性.
结论:
- 精密瘤学正在彻底改变罕见的中枢神经系统瘤治疗.
- 集成由分子瘤板指导的向疗法至关重要.
- 未来的研究应该专注于优化治疗时间,组合,耐药性机制,以及开发新的生物标志物和液体活检工具.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


